Hydroxyurea lowers total medical costs for pediatric sickle cell anemia

09/3/2013 | DoctorsLounge.com

Despite having higher outpatient costs, hydroxyurea treatment for children with sickle cell anemia had a 21% lower total estimated annual cost than placebo, according to a study in the journal Pediatrics. The hydroxyurea group had fewer hospitalizations compared with the placebo group, but both had similar lengths of stay.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX